Search is not available for this dataset
identifier
stringlengths 12
47
⌀ | website
stringclasses 32
values | filename
stringlengths 5
255
⌀ | title
stringlengths 0
2.23k
⌀ | word_count
int64 1
1.89M
⌀ | character_count
float64 16
7.09M
⌀ | type
stringclasses 2
values |
|---|---|---|---|---|---|---|
<urn:uuid:956c3aef-c6f1-4bf9-acd8-d110e4af9793> | efs.sante.fr | null | Efs Ra Maquette Sr Lr.Pdf | 18,788 | null | web |
dadd771c9ad90816f700349088f86159 | efs.sante.fr | EFS_RA2020_cahier%20corporate_vFINAL_EN_WEB.txt | Efs Ra2020 Cahier Corporate Vfinal En Web | 14,849 | 97,773 | pdf |
<urn:uuid:56371c7e-af41-4710-8b77-aeefae362f1d> | efs.sante.fr | null | Efs Ra2020 Cahier Corporate Vfinal En Web.Pdf | 13,791 | null | web |
6e636cc75f7cbe80d410fa14d63d07c2 | efs.sante.fr | EFS_RA2020_cahier%20Manifeste_vFINAL_EN_WEB.txt | Efs Ra2020 Cahier Manifeste Vfinal En Web | 4,009 | 24,096 | pdf |
<urn:uuid:7dafb375-008b-4cf4-bb53-38cde8051a3c> | efs.sante.fr | null | Efs Ra2020 Cahier Manifeste Vfinal En Web.Pdf | 3,801 | null | web |
8f5552a8ab918081945e9910decc4ff8 | efs.sante.fr | EFS_Rapport%20De%CC%81ontologue_VD.txt | Efs Rapport DéOntologue Vd | 5,515 | 36,528 | pdf |
<urn:uuid:2fbe42d3-9ca1-419a-be30-b8e728680f1d> | efs.sante.fr | null | Efs Rapport DéOntologue Vd.Pdf | 5,332 | null | web |
1adf3383c5fabd422bcd3318a619e4e0 | efs.sante.fr | EFS_Recherche_Cart-cells.txt | Efs Recherche Cart Cells | 651 | 4,498 | pdf |
<urn:uuid:3547d41f-e294-454a-87af-e5dcbb30f9c5> | efs.sante.fr | null | Efs Recherche Cart Cells.Pdf | 401 | null | web |
79fbebf2436e6763e8893a1829077e16 | efs.sante.fr | EFS_Relance-urgence_23juin2021.txt | Efs Relance Urgence 23Juin2021 | 581 | 3,779 | pdf |
<urn:uuid:c299119f-da37-48f6-80fe-a652e99e60e6> | efs.sante.fr | null | Efs Relance Urgence 23Juin2021.Pdf | 298 | null | web |
08a79e21f1716ccb9d30de1b28c7ba6b | efs.sante.fr | EFS_reserves-critiques.txt | Efs Reserves Critiques | 885 | 5,683 | pdf |
<urn:uuid:ea549530-2e7d-4017-86a6-e0c776fecef4> | efs.sante.fr | null | Efs Reserves Critiques.Pdf | 572 | null | web |
93d15d7fa7f52d00d2feda475a40aa4b | efs.sante.fr | EFS_Semaine_sangs_rares_novembre21_web.txt | Efs Semaine Sangs Rares Novembre21 Web | 654 | 4,244 | pdf |
<urn:uuid:8daede94-bf84-4e81-8a7c-1718fe837a9e> | efs.sante.fr | null | Efs Semaine Sangs Rares Novembre21 Web.Pdf | 480 | null | web |
6cbcd936b4447f14de316f16ba1d00af | efs.sante.fr | EFS_SOCIAL_LAB_N%C2%B01.txt | Efs Social Lab N°1 | 4,849 | 30,917 | pdf |
d68ec16c059764d072d2dddada63c4ca | efs.sante.fr | EFS_SOCIAL_LAB_N%C2%B01_ANGLAIS_BD.txt | Efs Social Lab N°1 Anglais Bd | 4,459 | 28,153 | pdf |
<urn:uuid:50c66c1c-2fea-44a0-90df-2d37fe99f208> | efs.sante.fr | null | Efs Social Lab N°1 Anglais Bd.Pdf | 4,417 | null | web |
<urn:uuid:6d5cb76a-5a7f-409e-ba40-006cf7d39a3f> | efs.sante.fr | null | Efs Social Lab N°1.Pdf | 4,802 | null | web |
380aa69fbd2847617215cbfe95646495 | efs.sante.fr | EFS-Technology%20Offer%20-%20%20HDL%20for%20the%20treatment%20and%20prevention%20of%20GvHD%20and%20CRS-december%202020.txt | Efs Technology Offer Hdl For The Treatment And Prevention Of Gvhd And Crs December 2020 | 416 | 2,976 | pdf |
<urn:uuid:4fc48de2-de55-4b58-a644-b692e824fa62> | efs.sante.fr | null | Efs Technology Offer Hdl For The Treatment And Prevention Of Gvhd And Crs December 2020.Pdf | 340 | null | web |
30b81dc164fca8aeab11a81bd91b4f61 | efs.sante.fr | EFS_Technology%20Offer_An%20innovative%20procedure%20for%20preserving%20cells%2C%20tissues%20or%20organs%20in%20hypothermia-%20December%202020.txt | Efs Technology Offer An Innovative Procedure For Preserving Cells, Tissues Or Organs In Hypothermia December 2020 | 354 | 2,566 | pdf |
<urn:uuid:e5e98d68-1cd7-4979-b87d-20918a9432be> | efs.sante.fr | null | Efs Technology Offer An Innovative Procedure For Preserving Cells, Tissues Or Organs In Hypothermia December 2020.Pdf | 328 | null | web |
6b9159d6468c33255351c414d1f024e5 | efs.sante.fr | EFS_Technology%20Offer_Injectable%20solution%20for%20cell%20preservation-december%202020.txt | Efs Technology Offer Injectable Solution For Cell Preservation December 2020 | 403 | 2,734 | pdf |
<urn:uuid:6d8a3d1c-9231-41e9-b40d-22dd286230f5> | efs.sante.fr | null | Efs Technology Offer Injectable Solution For Cell Preservation December 2020.Pdf | 323 | null | web |
499a9c98758467b9e9c1945990ea2cb6 | efs.sante.fr | EFS_Technology%20Offer_Method%20for%20the%20production%20of%20human%20brown%20and%20beige%20adipocytes-december%202020.txt | Efs Technology Offer Method For The Production Of Human Brown And Beige Adipocytes December 2020 | 376 | 2,710 | pdf |
<urn:uuid:352f92bd-8481-43ee-b50e-69ed940bf450> | efs.sante.fr | null | Efs Technology Offer Method For The Production Of Human Brown And Beige Adipocytes December 2020.Pdf | 295 | null | web |
a6b6298d8d46a1685302630060a8aad8 | efs.sante.fr | EFS-Technology%20Offer_Polythiols%20probes-december%202020.txt | Efs Technology Offer Polythiols Probes December 2020 | 374 | 2,840 | pdf |
<urn:uuid:69f40ab1-f7be-4771-b99b-f697b34e9b3a> | efs.sante.fr | null | Efs Technology Offer Polythiols Probes December 2020.Pdf | 304 | null | web |
8337e790fbb23aaedda4723c9bbabd4c | efs.sante.fr | EFS_Technology%20Offer_SNP%20genotyping-december%202020.txt | Efs Technology Offer Snp Genotyping December 2020 | 353 | 2,586 | pdf |
<urn:uuid:e7a9f1e1-e808-4cc7-a99f-6030ef4752a5> | efs.sante.fr | null | Efs Technology Offer Snp Genotyping December 2020.Pdf | 267 | null | web |
faaede41739ba6ea2a56f3b9fdbd5584 | efs.sante.fr | EFS_Technology%20offer_TLR4%20as%20a%20new%20target%20for%20Multiple%20Myeloma%20treatment_%20December%202020.txt | Efs Technology Offer Tlr4 As A New Target For Multiple Myeloma Treatment December 2020 | 430 | 2,979 | pdf |
<urn:uuid:0ba648b2-5d34-4731-978f-43cfc5f35a58> | efs.sante.fr | null | Efs Technology Offer Tlr4 As A New Target For Multiple Myeloma Treatment December 2020.Pdf | 354 | null | web |
1c310f0f0a68397195f3c70997d509ef | efs.sante.fr | EFS_TMC_PocketMemo_asso_WEB.txt | Efs Tmc Pocketmemo Asso Web | 606 | 3,678 | pdf |
<urn:uuid:cf0829b9-3a59-49ba-a794-ccfd84b44c62> | efs.sante.fr | null | Efs Tmc Pocketmemo Asso Web.Pdf | 544 | null | web |
96311436647aefa3703219f177b39962 | efs.sante.fr | EFS_vaccination-don-sang.txt | Efs Vaccination Don Sang | 609 | 3,887 | pdf |
<urn:uuid:b11a3676-a216-4e79-b533-23e77f6091f0> | efs.sante.fr | null | Efs Vaccination Don Sang.Pdf | 370 | null | web |
<urn:uuid:1bec66c2-bea8-4580-a4aa-30d7282614e7> | dondesang.efs.sante.fr | null | Efs X Cafe Joyeux | 173 | null | web |
fdaa26961c50568058025dba1e2b76c0 | efs.sante.fr | EFSNews_38_d%C3%A9cembre2020.txt | Efsnews 38 Décembre2020 | 1,135 | 7,076 | pdf |
<urn:uuid:cdb7c330-092f-4fe3-8e93-c35810935167> | efs.sante.fr | null | Efsnews 38 Décembre2020.Pdf | 1,044 | null | web |
9c5e21641244ddc2631928fc5212033f | efs.sante.fr | EFSNews_39_mars2021.txt | Efsnews 39 Mars2021 | 10,447 | 67,008 | pdf |
4e4024b6b67c5ca877b1389f2c5258c6 | efs.sante.fr | EFSNews_39_mars2021_0.txt | Efsnews 39 Mars2021 0 | 579 | 3,663 | pdf |
<urn:uuid:afb102cb-b348-401e-87df-e3cce16b852c> | efs.sante.fr | null | Efsnews 39 Mars2021 0.Pdf | 573 | null | web |
<urn:uuid:78812928-0b07-411b-a49f-b7847ac459fc> | efs.sante.fr | null | Efsnews 39 Mars2021.Pdf | 9,697 | null | web |
cb5e7bfc30234b3c90c339d79aadcbbe | efs.sante.fr | EFSNews%23PLR2020.txt | Efsnews#Plr2020 | 3,147 | 19,503 | pdf |
<urn:uuid:09662898-e40d-449b-90cd-c1b0b3852154> | efs.sante.fr | null | Efsnews#Plr2020.Pdf | 3,007 | null | web |
<urn:uuid:2a86d986-d398-49eb-b073-0114fe1b0ab8> | has-sante.fr | null | Efudix Fluorouracile | 50 | null | web |
<urn:uuid:72135156-30cd-4ac7-9c65-bbcda46ddbac> | sante.gouv.fr | null | Egal Acces A Des Soins Appropries | 168 | null | web |
<urn:uuid:68566584-70ee-4837-accf-2f42927c931f> | drogues.gouv.fr | null | Egalite Diversite | 54 | null | web |
<urn:uuid:5f963738-dfc1-4ceb-a515-bcd6a1e652e3> | cng.sante.fr | null | Egalite Femmes Hommes | 1,605 | null | web |
cd27525a05d28fddd724fcc4b601b131 | atih.sante.fr | egf.txt | Egf | 1,846 | 11,141 | pdf |
<urn:uuid:62281c3e-7c25-462a-bbee-c895cad00b29> | e-cancer.fr | null | Egf Promotes Dkk1 Transcription In Hepatocellular Carcinoma By Enhancing The Phosphorylation And Acetylation Of Histone H3 | 277 | null | web |
<urn:uuid:ab4aa4b9-95f0-48fa-9ea1-bcc0af96d936> | e-cancer.fr | null | Egf Receptor Activates Met Through Map Kinases To Enhance Non Small Cell Lung Carcinoma Invasion And Brain Metastasis | 225 | null | web |
<urn:uuid:a45b55e3-5bc3-421b-a824-0067203cc797> | e-cancer.fr | null | Egf Receptor Is Required For Kras Induced Pancreatic Tumorigenesis | 203 | null | web |
<urn:uuid:f9aebe3f-bc96-4976-adab-3400a347d065> | e-cancer.fr | null | Egf Receptor Signaling Is Essential For K Ras Oncogene Driven Pancreatic Ductal Adenocarcinoma | 224 | null | web |
<urn:uuid:05e9b45c-00a7-4d26-9cb7-2cd98b600b05> | atih.sante.fr | null | Egf.Pdf | 1,737 | null | web |
ca82bbc06418a43768861b28dd92e16a | atih.sante.fr | egfenf.txt | Egfenf | 1,535 | 9,368 | pdf |
<urn:uuid:26e75ad2-ad66-4be2-90b3-06246b459d58> | e-cancer.fr | null | Egfl6 Promotes Breast Cancer By Simultaneously Enhancing Cancer Cell Metastasis And Stimulating Tumor Angiogenesis | 215 | null | web |
<urn:uuid:fc4dfa01-183f-4871-9c0c-40ea5ea35381> | e-cancer.fr | null | Egfr Activation Limits The Response Of Liver Cancer To Lenvatinib | 191 | null | web |
<urn:uuid:e32ab378-1820-414b-813c-71d445b4edb1> | e-cancer.fr | null | Egfr Amplification And Outcome In A Randomised Phase Iii Trial Of Chemotherapy Alone Or Chemotherapy Plus Panitumumab For Advanced Gastro Oesophageal Cancers | 262 | null | web |
<urn:uuid:e473a1fa-0ce7-4f70-ab2f-82afdd2741a6> | e-cancer.fr | null | Egfr Amplification In Metastatic Colorectal Cancer | 254 | null | web |
<urn:uuid:b2fc010f-2e6c-4355-9819-cc1b1fc5fa03> | e-cancer.fr | null | Egfr Amplified And Overexpressing Glioblastomas And Association With Better Response To Adjuvant Metronomic Temozolomide | 281 | null | web |
<urn:uuid:b491e26d-411f-4cf1-9e4b-c9e0e52e2e82> | e-cancer.fr | null | Egfr And Her2 Inhibition In Pancreatic Cancer | 181 | null | web |
<urn:uuid:76157c8f-70e6-4cdd-b504-334bc89eaa55> | e-cancer.fr | null | Egfr And Kras Mutation Status In Non Small Cell Lung Cancer Occurring In Hiv Infected Patients | 252 | null | web |
<urn:uuid:23087e6a-63f8-4343-9827-68462e0bf365> | e-cancer.fr | null | Egfr Antibodies In Resectable Metastatic Colorectal Liver Metastasis More Harm Than Benefit | 333 | null | web |
<urn:uuid:a0a33d2e-552a-4d94-a8a6-e05b06162d86> | e-cancer.fr | null | Egfr Arf6 Regulation Of Hh Signalling Stimulates Oncogenic Ras Tumour Overgrowth | 165 | null | web |
<urn:uuid:732be107-84fd-4519-aa27-cac7f81c7545> | e-cancer.fr | null | Egfr As A Potential Therapeutic Target For A Subset Of Muscle Invasive Bladder Cancers Presenting A Basal Like Phenotype | 187 | null | web |
<urn:uuid:5291856e-c234-4ec7-9ec9-33a8a53ef474> | e-cancer.fr | null | Egfr As A Stable Marker Of Prostate Cancer Dissemination To Bones | 205 | null | web |
<urn:uuid:397a9341-a1fe-4f46-8f36-d100f7d990c0> | e-cancer.fr | null | Egfr Based Bioradiotherapy In Scchn | 140 | null | web |
<urn:uuid:82e54e24-2b6d-4f02-86fb-58bf208c67de> | e-cancer.fr | null | Egfr Biomarkers Predict Benefit From Vandetanib In Combination With Docetaxel In A Randomized Phase Iii Study Of Second Line Treatment For Patients With Advanced Non Small Cell Lung Cancer | 302 | null | web |
<urn:uuid:7e4c7114-a976-48ee-9887-6ec004c08dab> | e-cancer.fr | null | Egfr Ca Repeat Polymorphism Predict Clinical Outcome In Egfr Mutation Positive Nsclc Patients Treated With Erlotinib | 260 | null | web |
<urn:uuid:92df097a-3718-4965-af83-c6ce1f853a87> | e-cancer.fr | null | Egfr Directed Antibodies Increase The Risk Of Severe Infection In Cancer Patients | 167 | null | web |
<urn:uuid:e121c827-d06b-494c-8420-c1efa76e82ac> | e-cancer.fr | null | Egfr Directed Treatments In Scchn | 67 | null | web |
<urn:uuid:6e8853dc-c9db-4a51-a15e-25f881646b2a> | e-cancer.fr | null | Egfr Driven Lung Adenocarcinomas Coopt Alveolar Macrophage Metabolism And Function To Support Egfr Signaling And Growth | 160 | null | web |
<urn:uuid:b70d0056-f42e-4ae7-adbf-94c7b2dae87a> | e-cancer.fr | null | Egfr Gene Copy Number As A Predictive Biomarker For The Treatment Of Metastatic Colorectal Cancer With Anti Egfr Monoclonal Antibodies A Metaanalysis | 349 | null | web |
<urn:uuid:f312f6f4-e2cb-4637-b20c-724e7bdc03c8> | e-cancer.fr | null | Egfr Gene Copy Number As A Predictive Biomarker For The Treatment Of Metastatic Colorectal Cancer With Anti Egfr Monoclonal Antibodies A Metaanalysis | 365 | null | web |
<urn:uuid:54e33310-92c5-45bb-9859-2b290ebd4e23> | e-cancer.fr | null | Egfr Has A Tumour Promoting Role In Liver Macrophages During Hepatocellular Carcinoma Formation | 152 | null | web |
<urn:uuid:1e579ca7-9f99-43df-97e0-ead0ca395689> | e-cancer.fr | null | Egfr Inhibitors As Adjuvant Therapy For Resected Non Small Cell Lung Cancer Harboring Egfr Mutations | 411 | null | web |
<urn:uuid:3821fd51-4216-459d-b7d2-22aaf21ac50a> | e-cancer.fr | null | Egfr Inhibitors For Wild Type Egfr Nsclc To Use Or Not To Use | 73 | null | web |
<urn:uuid:4ea9e4c8-6df6-4aba-84df-891341072d7a> | e-cancer.fr | null | Egfr Is A Master Switch Between Immunosuppressive And Immunoactive Tumor Microenvironment In Inflammatory Breast Cancer | 182 | null | web |
<urn:uuid:ef38d54a-4559-41e4-9268-3cbab4547669> | e-cancer.fr | null | Egfr Jip 4 Jnk2 Signaling Attenuates Cetuximab Mediated Radiosensitization Of Squamous Cell Carcinoma Cells | 174 | null | web |
<urn:uuid:6cce8293-c08d-41a5-8bed-06aa5ab8ef0b> | e-cancer.fr | null | Egfr Mediated Beclin 1 Phosphorylation In Autophagy Suppression Tumor Progression And Tumor Chemoresistance | 239 | null | web |
<urn:uuid:74d0ee75-238b-4dc6-b83f-02b9b8a75def> | e-cancer.fr | null | Egfr Modulates Microrna Maturation In Response To Hypoxia Through Phosphorylation Of Ago2 | 274 | null | web |
<urn:uuid:162e1c62-a6e0-4ea7-8643-b4989faec38b> | e-cancer.fr | null | Egfr Monoclonal Antibody Biomarkers In Advanced Nsclc From Translational Research To Clinical Implementation | 88 | null | web |
<urn:uuid:e99d954a-f25c-4da5-aa02-7313775fe4ab> | e-cancer.fr | null | Egfr Mutant Adenocarcinomas That Transform To Small Cell Lung Cancer And Other Neuroendocrine Carcinomas Clinical Outcomes | 297 | null | web |
<urn:uuid:fe38dc86-9fc3-41b2-a4b4-11f167dbea5d> | e-cancer.fr | null | Egfr Mutation Impact On Definitive Concurrent Chemoradiation Therapy For Inoperable Stage Iii Adenocarcinoma | 297 | null | web |
<urn:uuid:b40a23a1-ae18-4d27-a946-71a4d9331cec> | e-cancer.fr | null | Egfr Mutation Prevalence Real World Treatment Patterns And Outcomes Among Patients With Resected Early Stage Non Small Cell Lung Cancer In Canada | 299 | null | web |
<urn:uuid:d1b3cc7b-0c60-4f59-9a2a-6ed495c08bcd> | e-cancer.fr | null | Egfr Mutations And Alk Rearrangements Are Associated With Low Response Rates To Pd 1 Pathway Blockade In Non Small Cell Lung Cancer Nsclc A Retrospective Analysis | 273 | null | web |
<urn:uuid:0a80c65f-9cd2-4d3a-8200-e36d38c37ce2> | e-cancer.fr | null | Egfr Mutations And Clinical Outcomes Of Chemotherapy For Advanced Non Small Cell Lung Cancer A Meta Analysis | 297 | null | web |
<urn:uuid:4acfa683-3e2e-4550-93cb-6e83c22b47aa> | e-cancer.fr | null | Egfr Mutations In Non Small Cell Lung Cancer Find Divide And Conquer | 152 | null | web |
<urn:uuid:d11c935b-6a53-481b-a47f-b731252f5af3> | e-cancer.fr | null | Egfr Phosphorylates Tumor Derived Egfrviii Driving Stat3 5 And Progression In Glioblastoma | 175 | null | web |
<urn:uuid:8648ce3e-068a-40f5-9bce-1215152ae203> | e-cancer.fr | null | Egfr Ras Induced Ccl20 Production Modulates The Tumour Microenvironment | 202 | null | web |
<urn:uuid:58d90aa7-4a63-4994-a1ba-22a9a1738ab1> | e-cancer.fr | null | Egfr Tki Associated Interstitial Pneumonitis In Nivolumab Treated Patients With Non Small Cell Lung Cancer | 340 | null | web |
<urn:uuid:99d5242b-7e54-430c-9429-8d84a7f11fc3> | e-cancer.fr | null | Egfr Tki Plus Anti Angiogenic Drugs In Egfr Mutated Nsclc A Meta Analysis Of Randomized Clinical Trials | 258 | null | web |
<urn:uuid:58f1ca3e-b3d1-465b-93dd-dad0c2aa0309> | e-cancer.fr | null | Egfr Variant Heterogeneity In Glioblastoma Resolved Through Single Nucleus Sequencing | 192 | null | web |
<urn:uuid:d585e48f-12ab-4965-b4e6-d0eaee85073c> | e-cancer.fr | null | Egg Consumption In Relation To Glioma A Case Control Study | 232 | null | web |
<urn:uuid:98a1af9d-8f99-4da0-8c4c-6faf5b35265e> | e-cancer.fr | null | Egln3 Attenuates Gastric Cancer Cell Malignant Characteristics By Inhibiting Jmjd8 Nf Kb Signalling Activation Independent Of Hydroxylase Activity | 170 | null | web |
<urn:uuid:e588913b-056e-4f69-b45c-babf3e709e81> | alcool-info-service.fr | null | Egoistement | 393 | null | web |
<urn:uuid:c0455e41-4522-45f2-86b8-0f94fdda38b4> | e-cancer.fr | null | Egr1 Decreases The Malignancy Of Human Non Small Cell Lung Carcinoma By Regulating Krt18 Expression | 197 | null | web |
<urn:uuid:92e3b143-6ed0-4cd1-b6bd-aad0c0ce16b3> | agence-biomedecine.fr | null | Egt Liste Des Entites Fonctionnelles 2.Pdf | 3,516 | null | web |
Subsets and Splits